What happens when a licensed peanut allergy treatment gets pulled from the market — not because it didn't work, but because nobody could afford it?

Dr. Adam Fox, Professor of Pediatric Allergy at King's College London, joins Dr. Doug Jones to unpack that exact scenario and what it means for families on both sides of the Atlantic.This episode gets into the real-world consequences of how healthcare systems shape treatment. In the UK, the National Health Service approved Palforzia for peanut oral immunotherapy — then put zero funding behind it. Fewer than 100 children across the entire country received it through the NHS. Meanwhile in the US, allergists were already treating patients effectively with real food, making a pharmaceutical peanut powder feel unnecessary. Now that Palforzia is being pulled, the ripple effects look very different depending on where you live. Dr. Fox and Dr. Jones also talk about what's driving the global collaboration movement in food allergy treatment, how the right mindset can change a patient's OIT outcome, and why the grass isn't always greener when it comes to US vs. UK medicine.

🩺 Become a patient at GAIN: myimmunenetwork.com

📱Follow Dr. Doug Jones: @drdougjones on Instagram and TikTok🌐 Learn more: drdougjones.com